QED Therapeutics, an affiliate of BridgeBio Pharma, is a biotechnology company focused on developing and commercializing infigratinib, an orally administered, FGFR tyrosine kinase inhibitor. QED Therapeutics is evaluating infigratinib in clinical studies for the treatment of achondroplasia, cholangiocarcinoma, and urothelial carcinoma with FGFR genomic alterations. QED plans to conduct further clinical trials to evaluate the potential for infigratinib to treat individuals with other FGFR-driven disorders. QED is led by a team of veteran biotechnology executives.
BridgeBio Pharma, Inc. (BridgeBio) is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio's pipeline of over 30 development programs ranges from early science to advanced clinical trials, and its commercial organization is focused on delivering the company's first two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.